The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global hospital acquired disease testing market size was valued at US$ 7.32 Billion in 2020.
According to the estimates by IMARC Group, the global hospital acquired disease testing market is expected to exhibit strong growth during 2021-2026.
Rising incidences of HAIs upon exposure to infected patients, contaminated linens, medical equipment, etc., are currently driving the market for hospital acquired disease testing.
Several technological advancements have led to the introduction of microarrays, solid phase hybridization, polymerase chain reaction (PCR) and real-time location systems (RTLSs) for detecting and monitoring HAIs, thereby representing the one of the key trends in the global hospital acquired disease testing market.
Sudden outbreak of the COVID-19 pandemic has led to the rising demand for advanced and effective testing devices for hospital acquired diseases based on the increasing risk of coronavirus contraction upon hospital visits.
On the basis of the indication, the market has been bifurcated into urinary tract infection, surgical site infection (SSI), pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus (MRSA), and others. Amongst these, urinary tract infection (UTI) holds the majority of the total market share.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
The key companies in the global hospital acquired disease testing market are Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at